WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
This Quarter Return
-3.42%
1 Year Return
-17.41%
3 Year Return
-27.69%
5 Year Return
+67.02%
10 Year Return
–
AUM
$2.08B
AUM Growth
+$2.08B
(-16%)
Cap. Flow
-$287M
Cap. Flow
% of AUM
-13.81%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
5
Reduced
2
Closed
1
Top Buys
| 1 |
Theravance Biopharma
TBPH
|
$35.1M |
| 2 |
Biogen
BIIB
|
$20.4M |
| 3 |
AbbVie
ABBV
|
$12.7M |
| 4 |
Gilead Sciences
GILD
|
$9.13M |
| 5 |
Prothena Corp
PRTA
|
$431K |
Top Sells
| 1 |
RAI
Reynolds American Inc
RAI
|
$359M |
| 2 |
Alkermes
ALKS
|
$5.44M |
| 3 |
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
|
$383K |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $703M | 33.86% | 11,232,758 +202,958 | +2% | +$12.7M |
|
|
2
Prothena Corp
PRTA
$441M
| $507M | 24.42% | 10,310,511 +8,760 | +0.1% | +$431K |
|
|
3
Alkermes
ALKS
$4.78B
| $414M | 19.94% | 7,451,128 -97,905 | -1% | -$5.44M |
|
|
4
Theravance Biopharma
TBPH
$699M
| $335M | 16.13% | 10,507,608 +1,100,471 | +12% | +$35.1M |
|
|
5
Biogen
BIIB
$19.4B
| $64.9M | 3.13% | 248,530 +78,100 | +46% | +$20.4M |
|
|
6
Gilead Sciences
GILD
$140B
| $44M | 2.12% | 614,300 +127,500 | +26% | +$9.13M |
|
|
NWBO
7
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
| $8.64M | 0.42% | 24,815,028 -1,100,909 | -4% | -$383K |
|
|
RAI
8
DELISTED
Reynolds American Inc
RAI
| – | – | -7,608,324 | Closed | -$359M |
|